Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases.
about
Serum inhibin A and inhibin B levels in epithelial ovarian cancer patients.Plasma levels of MMP-7 and TIMP-1 in laboratory diagnostics and differentiation of selected histological types of epithelial ovarian cancers.Preoperative evaluation of risk of ovarian malignancy algorithm index in prediction of malignancy of adnexal massesDoes risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis.Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese womenSerum HE4 is more suitable as a biomarker than CA125 in Chinese women with benign gynecologic disordersM-CSF in a new biomarker panel with HE4 and CA 125 in the diagnostics of epithelial ovarian cancer patientsComparison of specific ovarian tumor markers by elecsys analyzer 2010Human epididymis protein 4 reference limits and natural variation in a Nordic reference populationSerum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer managementEvaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125Overexpression of centromere protein K (CENPK) in ovarian cancer is correlated with poor patient survival and associated with predictive and prognostic relevance.Validity of Cancer Antigen-125 (CA-125) and Risk of Malignancy Index (RMI) in the Diagnosis of Ovarian CancerInterpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer.Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors.Diagnostic Power of Vascular Endothelial Growth Factor and Macrophage Colony-Stimulating Factor in Breast Cancer Patients Based on ROC Analysis.Serum anti-müllerian hormone levels in patients with epithelial ovarian cancer.Can ROMA algorithm stratify ovarian tumor patients better when being based on specific age ranges instead of the premenopausal and postmenopausal status?Diagnostic usefulness of the Risk of Ovarian Malignancy Algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay for CA125.HE4 Serum Levels in Patients with BRCA1 Gene Mutation Undergoing Prophylactic Surgery as well as in Other Benign and Malignant Gynecological Diseases.HE4 tumor marker concentration in neoplastic peritoneal effusion and in peritoneal fluid associated with benign gynecological diseasesAnalysis of serum level of HE4 and CA125 considering selected risk factors among patients with endometrioid endometrial cancer.Diagnostic accuracy of urine HE4 in patients with ovarian cancer: a meta-analysis.Ovarian cancer: biomarker proteomic diagnosis in progress.The role of human epididymis protein 4 in the diagnosis of epithelial ovarian cancer.The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review.The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer.Outcome of elevated CA125 values from primary care following implementation of ovarian cancer guidelines.HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer.Human epididymis protein 4 (HE4) in benign and malignant diseases.
P2860
Q31153145-D714C021-205D-4BCE-A8BB-5B9113F4C790Q32173966-270677D1-174E-4F57-A337-324A330C0773Q33918256-88DA3335-7F19-4A28-A378-115032693F81Q34308808-9C22FD37-2C5E-48D1-BF99-6036F63E25CEQ35126762-BD0183A1-860B-400F-AF2C-84EBCC2F6A1AQ35207172-29444E78-A9D6-4B81-AD41-BC89616296A1Q35589339-BDFC4B0E-49C6-433C-9402-3D343C717B05Q35601405-52738765-4B2B-4C3B-B995-A91B0E16DC1DQ35605987-BE4A5CD5-9D69-4BB3-9C0A-99E5C2438FCDQ35612779-60C305D6-BE76-4857-95A7-D5CABB843525Q35830931-CE1B62D0-667F-4ACD-9F66-1220DF7C4F67Q36286844-83B86319-8D12-4EB3-8D2D-37FACA2A5BB2Q36370010-F7F66FBD-9A59-4789-98E6-2D7B2754EFA7Q36385490-5473F224-5AD7-4128-80F0-B6DBF866B156Q36752512-41F2870A-E6E4-4D7B-8DA2-2D54680D4C02Q36996525-2824DBE7-18DF-4EF4-BB37-DA4926D450EEQ37100214-0DD5939E-2E2B-4A8E-9560-005FDF818C71Q37100987-F92FD2AA-2E88-4F21-9A04-2EF6BEE23999Q37188163-17A87E1C-B8B0-4A7A-8C6B-7058BE5A187CQ37406838-92B35396-E17B-4D8D-AE6A-DC9493EC5E66Q37611329-38B1AED0-9691-4D30-9599-41EF44D694C6Q37613447-8AD60E6C-CF42-4197-ABCC-500BEBA3382AQ37657661-FD80AD1A-BEE4-42D8-B2F8-0F2BA52A5D5CQ37706040-DA15954C-37D1-4441-BB52-52B11C6B2998Q38040333-D08F86EE-3060-480A-ABBD-A589388C9F4DQ38388103-AF508350-91BE-444F-A665-2032D592D064Q38653169-DF289E12-FF7F-4194-999C-912DC9981846Q40485803-7D3D356F-0454-4967-A5B6-82590FF90E5DQ44774158-C5DEF15E-6744-4D7D-B18A-C38C9645C6C0Q47610637-5CCC66EC-76D8-4128-A3E7-12D121707183Q51091632-3F969CB8-8B27-412D-863A-CCA1742029CFQ51301242-D863B7AC-3403-4096-9B45-6ABDE93CE97C
P2860
Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Diagnostic performances of HE4 ...... and non-gynecologic diseases.
@en
Diagnostic performances of HE4 ...... and non-gynecologic diseases.
@nl
type
label
Diagnostic performances of HE4 ...... and non-gynecologic diseases.
@en
Diagnostic performances of HE4 ...... and non-gynecologic diseases.
@nl
prefLabel
Diagnostic performances of HE4 ...... and non-gynecologic diseases.
@en
Diagnostic performances of HE4 ...... and non-gynecologic diseases.
@nl
P2093
P1476
Diagnostic performances of HE4 ...... and non-gynecologic diseases.
@en
P2093
Duck Jin Hong
Eun Young Lee
Jong-Han Lee
Yongjung Park
P304
P356
10.1016/J.CLINBIOCHEM.2011.04.011
P50
P577
2011-04-22T00:00:00Z